Literature DB >> 34302771

Long-Term Outcomes and Risk Factors for Severe Vision Loss in Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV).

Timothy M Boyce1, S Scott Whitmore1, Katayoun Varzavand1, Stephen R Russell1, Elliott H Sohn1, James C Folk1, Edwin M Stone1, Ian C Han2.   

Abstract

Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is a rare disorder characterized by uveitis, retinal neovascularization, and retinal degeneration. We sought to describe the course of treated and untreated ADNIV and to identify risk factors for severe vision loss.
DESIGN: Observational case series.
METHODS: Clinical data from ADNIV patients from 4 families seen from 1967 through 2019 at a single academic, tertiary referral center were reviewed. The main outcome measures were visual acuity at baseline and follow-up, as well as risk factors for vision loss.
RESULTS: A total of 130 eyes from 65 ADNIV patients (45 female, 20 male; mean age 40.8 years, range 6-77 years) were included. Mean best corrected visual acuity (BCVA) at presentation was LogMAR 0.59 (about Snellen 20/80). Longitudinal analysis included 84 eyes from 42 patients (31 female, 11 male), with mean follow-up of 17.3 years (range 2-43.6 years). Mean BCVA at last follow-up was LogMAR 1.48 (about Snellen 20/600). The disease accelerated in the fifth decade of life, during which the majority of eyes went from normal vision or mild vision loss to at least moderate vision loss (20/70 Snellen equivalent); 25 eyes from 16 patients (29.8%;) showed a steep trajectory of vision loss to no light perception. Tractional retinal detachment was the greatest risk factor for severe vision loss (BCVA <20/200) on multivariable analysis (P < .05).
CONCLUSIONS: Patients with ADNIV have a high lifetime risk of severe vision loss. Tractional retinal detachment is an important risk factor for poor vision.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34302771      PMCID: PMC9177238          DOI: 10.1016/j.ajo.2021.07.015

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.488


  37 in total

1.  Bias-reduced and separation-proof GEE with small or sparse longitudinal binary data.

Authors:  Momenul Haque Mondol; M Shafiqur Rahman
Journal:  Stat Med       Date:  2019-02-22       Impact factor: 2.373

2.  Therapeutic drug repositioning using personalized proteomics of liquid biopsies.

Authors:  Gabriel Velez; Alexander G Bassuk; Diana Colgan; Stephen H Tsang; Vinit B Mahajan
Journal:  JCI Insight       Date:  2017-12-21

3.  Visual acuities "hand motion" and "counting fingers" can be quantified with the freiburg visual acuity test.

Authors:  Kilian Schulze-Bonsel; Nicolas Feltgen; Hermann Burau; Lutz Hansen; Michael Bach
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-03       Impact factor: 4.799

4.  Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy.

Authors:  K Ghasemi Falavarjani; M Modarres; A Hadavandkhani; A Karimi Moghaddam
Journal:  Eye (Lond)       Date:  2015-07-10       Impact factor: 3.775

5.  Erosive vitreoretinopathy. A new clinical entity.

Authors:  D M Brown; A E Kimura; T A Weingeist; E M Stone
Journal:  Ophthalmology       Date:  1994-04       Impact factor: 12.079

6.  Monozygotic twins with CAPN5 autosomal dominant neovascular inflammatory vitreoretinopathy.

Authors:  Hannah A Rowell; Alexander G Bassuk; Vinit B Mahajan
Journal:  Clin Ophthalmol       Date:  2012-12-06

7.  Analysis of a large choroideremia dataset does not suggest a preference for inclusion of certain genotypes in future trials of gene therapy.

Authors:  Paul R Freund; Yuri V Sergeev; Ian M MacDonald
Journal:  Mol Genet Genomic Med       Date:  2016-02-28       Impact factor: 2.183

8.  Proteomic insight into the pathogenesis of CAPN5-vitreoretinopathy.

Authors:  Gabriel Velez; Jing Yang; Angela S Li; Stephen H Tsang; Alexander G Bassuk; Vinit B Mahajan
Journal:  Sci Rep       Date:  2019-05-20       Impact factor: 4.379

9.  PROGRESSION OF SCOTOPIC SINGLE-FLASH ELECTRORETINOGRAPHY IN THE STAGES OF CAPN5 VITREORETINOPATHY.

Authors:  Peter H Tang; Tyson R Kinnick; James C Folk; MaryAnn Mahajan; Alexander G Bassuk; Stephen H Tsang; Vinit B Mahajan
Journal:  Retin Cases Brief Rep       Date:  2021-07-01

10.  An anti-CAPN5 intracellular antibody acts as an inhibitor of CAPN5-mediated neuronal degeneration.

Authors:  Yan Wang; Xiao Zhang; Zongming Song; Feng Gu
Journal:  Oncotarget       Date:  2017-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.